In HGSOC, most tumor cells harbor mutations in TP53, and mouse models have been recently developed with syngeneic murine ovarian cancer cells engineered to express mutant p53 protein via CRISPR/Cas9 [129]. This evidence concerns the gene TP53 and ovarian cancer.